Citations

Clear

16 citation(s) found for "Shi, Wen".

Spike ripples localize the epileptogenic zone best: an international intracranial study
Shi, Wen , Shaw, Dana , Walsh, Katherine G. , Han, Xue , Eden, Uri T. , Gliske, S. , Jacobs, Julia , Brinkmann, Benjamin H. , Worrell, Gregory A. , Kramer, Mark , Chu, Catherine J. , Gliske, Stephen V , Brinkmann, Benjamin H , Worrell, Gregory A , Kramer, Mark A , Chu, Catherine J , Richardson, Robert Mark , Stacey, William C. , Frauscher, Birgit , Thomas, John Paul

Mayo Clinic

Brain | February 7, 2024 | Volume: 147 | Issue: 7 | Pages: 2496-2506

10.1093/brain/awae037 | PMID 38325327 Get It

Abstract We evaluated whether spike ripples, the combination of epileptiform spikes and ripples, provide a reliable and improved biomarker for the epileptogenic zone compared with other leading interictal biomarkers in a multicentre, international study. We first validated an automated spike ripple detector on intracranial EEG recordings. We then applied this detector to subjects from four centres who subsequently underwent surgical resection with known 1-year outcomes. We evaluated the spike ripple rate in subjects cured after resection [International League Against Epilepsy Class 1 outcome (ILAE 1)] and those with persistent seizures (ILAE 2–6) across sites and recording types. We also evaluated available interictal biomarkers: spike, spike-gamma, wideband high frequency oscillation (HFO, 80–500 Hz), ripple (80–250 Hz) and fast ripple (250–500 Hz) rates using previously validated automated detectors. The proportion of resected events was computed and compared across subject outcomes and biomarkers. Overall, 109 subjects were included. Most spike ripples were removed in subjects with ILAE 1 outcome (P < 0.001), and this was qualitatively observed across all sites and for depth and subdural electrodes (P < 0.001 and P < 0.001, respectively). Among ILAE 1 subjects, the mean spike ripple rate was higher in the resected volume (0.66/min) than in the non-removed tissue (0.08/min, P < 0.001). A higher proportion of spike ripples were removed in subjects with ILAE 1 outcomes compared with ILAE 2–6 outcomes (P = 0.06). Among ILAE 1 subjects, the proportion of spike ripples removed was higher than the proportion of spikes (P < 0.001), spike-gamma (P < 0.001), wideband HFOs (P < 0.001), ripples (P = 0.009) and fast ripples (P = 0.009) removed. At the individual level, more subjects with ILAE 1 outcomes had the majority of spike ripples removed (79%, 38/48) than spikes (69%, P = 0.12), spike-gamma (69%, P = 0.12), wideband HFOs (63%, P = 0.03), ripples (45%, P = 0.01) or fast ripples (36%, P < 0.001) removed. Thus, in this large, multicentre cohort, when surgical resection was successful, the majority of spike ripples were removed. Furthermore, automatically detected spike ripples localize the epileptogenic tissue better than spikes, spike-gamma, wideband HFOs, ripples and fast ripples.
Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.
Chesney, Jason , Lewis, Karl D. , Medina, Theresa , Kluger, Harriet M. , Thomas, Sajeve , Domingo‐Musibay, Evidio , Pavlick, Anna C. , Whitman, Eric D. , Corrie, Philippa Gail, Hamid, Omid , Wu, Renee, Shi, Wen , Fardis, Maria, Sarnaik, Amod A. , Khushalani, Nikhil I. , Medina, Theresa Michelle , Martín‐Algarra, Salvador , Corrie, Philippa Gail, Lutzky, Jose , Weber, Jeffrey S. , Larkin, James , Kirkwood, John M.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 10006-10006

10.1200/jco.2020.38.15_suppl.10006 Get It

10006 Background: Treatment options are limited for patients with advanced melanoma who have progressed on checkpoint inhibitors and targeted therapies. Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) leverages and enhances the body’s natural defense against cancer and has shown durable responses in heavily pretreated melanoma patients. Methods: C-144-01 is a global Phase 2 open-label, multicenter study of efficacy & safety of lifileucel in patients with unresectable metastatic melanoma who have progressed on checkpoint inhibitors and BRAF/MEK inhibitors, if BRAFv600 mutant. We report on Cohort 2 (N = 66) patients who have received TIL. Tumors were resected at local institutions, processed in central GMP facilities for TIL production, manufactured, cryopreserved & shipped back to sites in a 22-day process. Therapy consisted of one week of lymphodepletion, a single lifileucel infusion, and up to 6 IL-2 doses. ORR was based on RECIST v1.1 by investigator assessment. Data cutoff was Feb 2, 2020. Results: Baseline characteristics: 3.3 mean prior therapies (anti-PD1 100%; anti-CTLA-4 80%; BRAF/MEK inhibitor 23%), high baseline tumor burden (106 mm mean target lesion sum of diameters), 44% liver/brain lesions, 40.9% LDH > ULN. ORR by investigator was 36.4% (2 CR, 22 PR) and DCR was 80.3%. Mean time to response was 1.9 months (range: 1.3-5.6). After a median study follow-up of 17.0 months, median DOR (mDOR) was still not reached. Six responders have progressed, 2 have died and 2 started other anti-cancer therapy without progression. The adverse event profile was consistent with the underlying advanced disease and the lymphodepletion and IL-2 regimens. Additional follow-up data will be available for presentation. Conclusions: Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if BRAFv600 mutant. Clinical trial information: NCT02360579.
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
Picozzi, Vincent J. , Rocha, Flavio G. , Helton, Scott , Mody, Kabir , Asbun, Horacio J. , Pishvaian, Michael J. , Jackson, Patrick G. , Etheridge, Tina, Carney, Mairead, Neff, Thomas B., Porter, Seth, Crans, Gerald , Valone, Frank H., Shi, Wen

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 4_suppl | Pages: 457-457

10.1200/jco.2016.34.4_suppl.457 Get It

457 Background: Curative therapy for PDAC is currently achievable through resection only, but ≤ 15% of patients are candidates for surgery. FG-3019, a recombinant human mAb to connective tissue growth factor (CTGF), plus gemcitabine (G) significantly reduced tumor growth, increased apoptosis and improved survival vs G alone in the KPC mouse model. Higher FG-3019 exposure and lower baseline (BL) CTGF were independently and significantly associated with improved overall median and 1-year survival (OS) in a Ph2a trial with G and erlotinib in stage 3 or 4 PDAC. Neoadjuvant treatment of LAPC with FG-3019 combined with multidrug therapy may change the fibrotic character of LAPC and thus may make it amenable to surgical resection and potentially improve OS. Methods: Patients with unresectable LAPC (confirmed by laparoscopy) are randomized to G/NP ±FG-3019 for 6-cycle/24-week treatment. Safety, efficacy, PK and changes in CT, PET, & CA19.9 from BL through end of treatment (EOT) are assessed. Up to 4 endoscopic ultrasound (EUS) guided core biopsies are collected at BL. Protein microarrays of pre- and post-treatment biopsies are prepared from tumor and stromal cells isolated by laser capture microdissection. Surgical exploration is performed in subjects who achieved the protocol-defined criteria for possible resection. Results: To date, 11 subjects were enrolled with 5 randomized to +FG-3019 arm. There were no complications from laparoscopy or EUS core biopsies that were clinically significant or delayed dosing. Per investigator assessment, no FG-3019-related SAEs were reported, nor any identified toxicity suspected from combination of FG-3019 with chemotherapy. Overall, CA19.9 mean change from BL was −62.7% at Week 8 (n = 8), and target lesions were reduced by 20.6% (n = 6) at Week 16. Three out of 4 subjects had PET SUVmax reductions of ≥ 30% at EOT. Additional data from protein microarrays will be presented. Conclusions: Based on the limited data collected so far, this trial design is feasible and the G/NP +FG-3019 combination is well-tolerated and appears to be active. Summary results on surgical exploration of subjects will be provided later. Clinical trial information: NCT02210559.
Aberrant Gene Regulation in Obstetric, Gynecologic, and Reproductive Diseases
Jiang, Shi‐Wen , Brost, Brian , Zhang, Dan , Ren, Chune

Mayo Clinic

BioMed Research International | August 23, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-2

10.1155/2015/187691 | PMID 26366409 Get It

Microarray Analysis on Gene Regulation by Estrogen, Progesterone and Tamoxifen in Human Endometrial Stromal Cells
Ren, Chun-E, Li, Jin‐Ping , Lyle, Christian, Dowdy, Sean C. , Podratz, Karl C. , Byck, David, Chen, Hai-Bin, Jiang, Shi-Wen, Chen, Hai-Bin , Dowdy, Sean, Zhu, Xueqiong , Jiang, Shi‐Wen

Mayo Clinic

International Journal of Molecular Sciences | March 13, 2015 | Volume: 16 | Issue: 3 | Pages: 5864-5885

10.3390/ijms16035864 | PMID 25782154 Get It

Epithelial stromal cells represent a major cellular component of human uterine endometrium that is subject to tight hormonal regulation. Through cell-cell contacts and/or paracrine mechanisms, stromal cells play a significant role in the malignant transformation of epithelial cells. We isolated stromal cells from normal human endometrium and investigated the morphological and transcriptional changes induced by estrogen, progesterone and tamoxifen. We demonstrated that stromal cells express appreciable levels of estrogen and progesterone receptors and undergo different morphological changes upon hormonal stimulation. Microarray analysis indicated that both estrogen and progesterone induced dramatic alterations in a variety of genes associated with cell structure, transcription, cell cycle, and signaling. However, divergent patterns of changes, and in some genes opposite effects, were observed for the two hormones. A large number of genes are identified as novel targets for hormonal regulation. These hormone-responsive genes may be involved in normal uterine function and the development of endometrial malignancies.
Human Placental TEF-5 Transactivates the Human Chorionic Somatomammotropin Gene Enhancer
Jiang, Shi-Wen, Wu, Kangjian, Eberhardt, Norman L., Jiang, Shi‐Wen

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 13 | Issue: 6 | Pages: 879-889

10.1210/mend.13.6.0288 | PMID 10379887 Get It

Human Chorionic Somatomammotropin Enhancer Function Is Mediated by Cooperative Binding of TEF-1 and CSEF-1 to Multiple, Low-Affinity Binding Sites
Jiang, Shi-Wen, Trujillo, Miguel A., Eberhardt, Norman L., Jiang, Shi‐Wen

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 11 | Issue: 9 | Pages: 1223-1232

10.1210/mend.11.9.9984 | PMID 9259314 Get It

HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival
Jiang, Shi-Wen, Chen, Hai-Bin , Dowdy, Sean C. , Fu, Alex Z., Attewell, John R., Kalogera, Eleftheria , Drapkin, Ronny , Podratz, Karl C. , Broaddus, Russell R. , Li, Jinping , Jiang, Shi‐Wen , Drapkin, Ronny

Mayo Clinic

International Journal of Molecular Sciences | November 19, 2013 | Volume: 14 | Issue: 11 | Pages: 22655-22677

10.3390/ijms141122655 | PMID 24252907 Get It

We investigated the HE4 variant-specific expression patterns in various normal tissues as well as in normal and malignant endometrial tissues. The relationships between mRNA variants and age, body weight, or survival are analyzed. ICAT-labeled normal and endometrial cancer (EC) tissues were analyzed with multidimensional liquid chromatography followed by tandem mass spectrometry. Levels of HE4 mRNA variants were measured by real-time PCR. Mean mRNA levels were compared among 16 normal endometrial samples, 14 grade 1 and 14 grade 3 endometrioid EC, 15 papillary serous EC, and 14 normal human tissue samples. The relationship between levels of HE4 variants and EC patient characteristics was analyzed with the use of Pearson correlation test. We found that, although all five HE4 mRNA variants are detectable in normal tissue samples, their expression is highly tissue-specific, with epididymis, trachea, breast and endometrium containing the highest levels. HE4-V0, -V1, and -V3 are the most abundant variants in both normal and malignant tissues. All variants are significantly increased in both endometrioid and papillary serous EC, with higher levels observed in grade 3 endometrioid EC. In the EC group, HE4-V1, -V3, and -V4 levels inversely correlate with EC patient survival, whereas HE4-V0 levels positively correlate with age. HE4 variants exhibit tissue-specific expression, suggesting that each variant may exert distinct functions in normal and malignant cells. HE4 levels appear to correlate with EC patient survival in a variant-specific manner. When using HE4 as a biomarker for EC management, the effects of age should be considered.
HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines
Li, Jinping , Mariani, Andrea , Chen, Dong , Klatt, Edward, Podratz, Karl C. , Drapkin, Ronny , Broaddus, Russell R. , Dowdy, Sean C. , Jiang, Shi‐Wen , Chen, Hai-Bin , Chen, Haibin , Klatt, Edward, Chen, Dong , Drapkin, Ronny

Mayo Clinic

International Journal of Molecular Sciences | March 15, 2013 | Volume: 14 | Issue: 3 | Pages: 6026-6043

10.3390/ijms14036026 | PMID 23502467 Get It

HE4, also known as WFDC2, is a useful biomarker for ovarian cancer when either used alone or in combination with CA125. HE4 is also overexpressed in endometrial cancer (EC), but its function in cancer cells is not clear. In this study, we investigate the role of HE4 in EC progression. An HE4-overexpression system was established by cloning the HE4 prototypic mRNA variant (HE4-V0) into a eukaryotic expression vector. Following transfection, stable clones in two EC cell lines were selected. The effects of HE4 overexpression on cell growth and function were measured with the use of cell proliferation assay, matrigel invasion, and soft agar gel colony formation assays. HE4-induced cancer cell proliferation in vivo was examined in a mouse xenograft model. HE4 overexpression significantly enhanced EC cell proliferation, matrigel invasion, and colony formation in soft agar. Moreover, HE4 overexpression promoted tumor growth in the mouse xenograft model. HE4 overexpression enhanced several malignant phenotypes in cell culture and in a mouse model. These results are consistent with our previous observation that high levels of serum HE4 closely correlate with the stage, myometrial invasion and tumor size in patients with EC. This study provides evidence that HE4 overexpression directly impacts tumor progression in endometrial cancer.
Protein Kinase C-Mediated Modulation of FIH-1 Expression by the Homeodomain Protein CDP/Cut/Cux
Li, Jin‐Ping , Wang, Enfeng , Dutta, Shamit K., Lau, Julie S., Jiang, Shi-Wen, Datta, Kaustubh , Jiang, Shi‐Wen , Mukhopadhyay, Debabrata

Mayo Clinic

Molecular and Cellular Biology | August 7, 2007 | Volume: 27 | Issue: 20 | Pages: 7345-7353

10.1128/mcb.02201-06 | PMID 17682059 Get It